UNSPSC 51393603: Bucladesine

This classification denotes a phosphodiesterase inhibitor with the molecular formula C18H24N5O8P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63X7MBT2LQ, chemically known as 16980-89-5 (sodium salt, monohydrate) but generally known as bucladesine, which bears US NIH Compound Identifier 9687. Bucladesine most often comes in base and sodium forms. European Medicines Agency schedules Bucladesine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05946MIG.

UNSPSC 51393603 Bucladesine, a Commodity code, nominally covers a specific pharmaceutical compound, but recent state and local opportunities tagged under this code show little alignment with its narrow scope. The most recent solicitation — Seminole County, Florida's IFB60459723LAS — seeks procurement of naloxone and drug deactivation systems rather than bucladesine itself. A second opportunity from the Texas Health and Human Services Commission (HHS0017013) is a Request for Information on direct-to-manufacturer prescription programs with no specific drug named. The mismatch between the code's nominal pharmaceutical substance and the actual work being solicited suggests that either the code is being applied inconsistently by issuing bodies or the recent opportunities are tagged incorrectly. State and local procurement offices issuing under this code include county health authorities and state health and human services agencies, but activity is sparse and geographically limited to what the recent block supports.

Seminole County, Florida posted the only concrete procurement in the recent-opportunities block — an IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the county's Community Health Building, due July 26, 2023. The Texas HHS Commission's RFI (posted April 3, 2026, due the same date) seeks vendor capabilities for direct-to-manufacturer prescription fulfillment but does not name bucladesine or any specific drug product. Given the sparse and geographically concentrated activity, the code mismatch, and the absence of recent bucladesine-specific solicitations, this Commodity code shows minimal relevant procurement activity for business development purposes at this time.